Published in J Immunother Cancer on April 21, 2015
Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med (2016) 3.00
Pembrolizumab. J Immunother Cancer (2015) 0.99
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer (2016) 0.99
Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation (2015) 0.80
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer (2016) 0.80
Why cure, why now? J Med Ethics (2016) 0.80
[The pathology of adverse events with immune checkpoint inhibitors]. Pathologe (2017) 0.78
Importance of metabolic rate to the relationship between the number of genes in a functional category and body size in Peto's paradox for cancer. R Soc Open Sci (2016) 0.75
A Century of Radiation Therapy and Adaptive Immunity. Front Immunol (2017) 0.75
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Lung Cancer (Auckl) (2017) 0.75
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol (2017) 0.75
Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy. JAAD Case Rep (2016) 0.75
[Lymphocytic myocarditis in a patient with metastatic clear cell renal cell carcinoma treated with Nivolumab]. Pathologe (2017) 0.75
Checkpoint Inhibitors: Applications for Autoimmunity. Curr Allergy Asthma Rep (2017) 0.75
Lung cancer as a cardiotoxic state: a review. Med Oncol (2017) 0.75
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8(+) T Cell Responses to Chronic Viral Infections and Cancer. Front Immunol (2017) 0.75
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest (2017) 0.75
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Progress in human tumour immunology and immunotherapy. Nature (2001) 6.97
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Update on myocarditis. J Am Coll Cardiol (2012) 3.12
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med (2003) 2.65
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
Myocarditis. Lancet (2011) 2.21
Acute viral myocarditis. Eur Heart J (2008) 1.65
Cancer: Antitumour immunity gets a boost. Nature (2014) 1.28
PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol (2012) 1.24
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol (2014) 1.18
PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol (2010) 1.02